Jacobs Levy Equity Management Inc. Has $1.19 Million Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Jacobs Levy Equity Management Inc. trimmed its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 34.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 314,939 shares of the company’s stock after selling 163,501 shares during the period. Jacobs Levy Equity Management Inc. owned 0.46% of Amylyx Pharmaceuticals worth $1,190,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. boosted its position in Amylyx Pharmaceuticals by 232.1% during the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock worth $26,000 after purchasing an additional 4,883 shares during the period. Fox Run Management L.L.C. bought a new position in Amylyx Pharmaceuticals during the fourth quarter worth $45,000. Alpine Global Management LLC bought a new position in Amylyx Pharmaceuticals during the fourth quarter worth $45,000. RPO LLC bought a new position in Amylyx Pharmaceuticals during the fourth quarter worth $46,000. Finally, EntryPoint Capital LLC bought a new position in Amylyx Pharmaceuticals during the fourth quarter worth $53,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, Director Bernhardt G. Zeiher bought 10,000 shares of the firm’s stock in a transaction on Thursday, March 20th. The shares were purchased at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $37,000. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO James M. Frates sold 10,896 shares of Amylyx Pharmaceuticals stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $3.47, for a total value of $37,809.12. Following the completion of the transaction, the chief financial officer now owns 290,988 shares in the company, valued at approximately $1,009,728.36. This represents a 3.61% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 48,980 shares of company stock valued at $168,627 over the last quarter. 11.70% of the stock is owned by corporate insiders.

Amylyx Pharmaceuticals Stock Up 7.1%

AMLX stock opened at $4.84 on Friday. The company has a market cap of $431.44 million, a PE ratio of -1.27 and a beta of -0.60. The business has a 50-day simple moving average of $4.14 and a 200 day simple moving average of $4.21. Amylyx Pharmaceuticals, Inc. has a 52 week low of $1.58 and a 52 week high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.03. On average, analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Leerink Partners raised shares of Amylyx Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $4.00 to $10.00 in a research report on Wednesday, May 7th. Mizuho lifted their target price on Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the stock an “outperform” rating in a report on Wednesday. HC Wainwright lifted their target price on Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, May 9th. Finally, Leerink Partnrs raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $9.83.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.